Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
CYP Stock Chart & Stats
AU$0.29
-AU$0.01(-4.17%)
At close: 4:00 PM EST
AU$0.29
-AU$0.01(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.14 - AU$0.44
Previous CloseN/A
Volume63.41K
Average Volume (3M)233.82K
Market Cap
AU$70.05M
Enterprise ValueAU$67.46M
Total Cash (Recent Filing)AU$5.05M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding237,454,380
10 Day Avg. Volume170,513
30 Day Avg. Volume233,823
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$6.40M
Bulls Say, Bears Say
Bulls Say
Zero Debt Balance SheetA debt-free capital structure materially reduces refinancing and interest-rate vulnerability, preserving optionality to fund trials or pursue partnerships. Over a 2–6 month horizon this strengthens negotiating leverage with partners and limits solvency risk while cash burn is addressed.
Very High Gross MarginsNear-100% gross margins indicate favorable unit economics for the platform if revenues scale, implying high incremental profitability on partnered or commercial sales. Structurally, this supports attractive royalty economics for licensing deals and efficient margin expansion once fixed costs are absorbed.
Proprietary Cymerus IPSC PlatformThe Cymerus iPSC-derived allogeneic MSC platform is a durable competitive asset enabling off-the-shelf therapies, scalable manufacturing and multi-indication development. This technology underpins partnership value and long-term revenue potential beyond any single program if clinical progress continues.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow forces reliance on external funding, creating dilution and execution risk. Over the medium term this can constrain trial timelines, manufacturing investment and bargaining power with partners unless cash flow reverses or large partner funding is secured.
Large Recurring Operating LossesVery large operating losses and deeply negative net margins show the business cannot currently self-sustain development or commercialization. This structural unprofitability increases dependency on milestone/licensing deals and heightens execution risk should partnering outcomes or clinical readouts slip.
Eroding Equity And AssetsA materially shrinking asset and equity base reduces the balance sheet buffer available for program funding or manufacturing scale-up. Even with no debt, capital erosion limits strategic flexibility and raises the probability of dilutive raises or constrained growth if revenues don't materialize.
Cynata Therapeutics Limited News
CYP FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest share price was AU$0.14 and its highest was AU$0.43 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is AU$70.05M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 150 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 237,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:CYP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYP Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
-179.37%
Trailing 12-Months
Asset Growth
-62.21%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Cynata Therapeutics Limited (CYP) is an Australian biotechnology company focused on the development and commercialization of innovative stem cell therapies. The company specializes in Cymerus™, a proprietary technology for manufacturing mesenchymal stem cells (MSCs) at scale. This platform enables the production of therapeutic stem cells without the limitation of donor availability, supporting the treatment of various diseases and medical conditions. Cynata's core products target applications in regenerative medicine, encompassing indications such as cardiovascular disease, respiratory ailments, and graft-versus-host disease (GvHD).
Technical Analysis
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―